Primary Immunodeficiency Disease
‘Giants’ to tackle primary immunodeficiencies for practicing physicians during conference
Primary immunodeficiencies are not as rare as they used to be, James Fernandez, MD, PhD, told Healio, and practicing allergist-immunologists need to be prepared to diagnose and treat them, often in collaboration with other specialists.
Genetic testing encouraged as part of immunodeficiency management
BOSTON — Genetic testing can play a positive role and help improve outcomes in managing immunodeficiencies, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
FDA approves Xembify for biweekly dosing, treatment-naïve patients
The FDA approved an expanded label for Xembify, a 20% subcutaneous immunoglobulin used to treat primary immunodeficiencies produced by Grifols, according to a company press release.
Top news of April: Difficult patients, inhaler price caps, genetic testing, more
Healio has compiled April’s most-read news in asthma and allergy.
Q&A: Newborn screenings improve severe immunodeficiency survival rates
Between 40 and 80 infants are born with severe combined immunodeficiency disorder each year in the United States and Canada. The disease is fatal without bone marrow transplants as infections overwhelm compromised immune systems.
Mavorixafor reduces infection rates among patients with WHIM syndrome
Daily treatment with mavorixafor improved outcomes among patients with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM syndrome, in the 4WHIM phase 3 clinical trial, according to the drug’s developer, X4 Pharmaceuticals.
FDA approves Hyqvia for children with primary immunodeficiency
The FDA has approved a supplemental biologics license application for the use of Hyqvia to treat primary immunodeficiency in children aged 2 to 16 years, according to a press release from Takeda.
FDA approves leniolisib for activated phosphoinositide 3-kinase delta syndrome
The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.
Cutaquig enables modified subcutaneous immunoglobulin infusion regimens
SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
COVID-19 lockdown lowered infection rates among patients with primary immunodeficiencies
LOUISVILLE, Ky. — Patients with primary immunodeficiency disease experienced fewer infections during the COVID-19 lockdown, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.